Ad is loading...
FSPHX vs HGHRX
FSPHX vs HGHRX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
FSPHX vs. HGHRX commentary
Dec 19, 2024
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSPHX is a StrongBuy and HGHRX is a Buy.
FUNDAMENTALS
Fundamentals
FSPHX has more cash in the bank: 7.51B vs. HGHRX (952M). FSPHX (0.00) and HGHRX (0.00) have matching dividends . FSPHX was incepted earlier than HGHRX: FSPHX (43 years) vs HGHRX (18 years). FSPHX is a more actively managed with annual turnover of: 40.00 vs. HGHRX (32.00). FSPHX (0) and HGHRX (0) have matching initial minimum investment requirements. FSPHX annual gain was more profitable for investors over the last year : 7.35 vs. HGHRX (-0.93). FSPHX return over 5 years is better than : 5.20 vs. HGHRX (-6.20).
| FSPHX | HGHRX | FSPHX / HGHRX | |
| Total Expense Ratio | N/A | N/A | - |
| Annual Report Gross Expense Ratio | N/A | N/A | - |
| Fund Existence | 43 years | 18 years | - |
| Gain YTD | 3.651 | -3.343 | -109% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 7.51B | 952M | 789% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 7.35 | -0.93 | -788% |
| Returns for 3 years | -4.79 | -10.96 | 44% |
| Returns for 5 years | 5.20 | -6.20 | -84% |
| Returns for 10 years | 34.71 | -3.78 | -918% |
View a ticker or compare two or three
VS
VS
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| UEMPX | 7.84 | N/A | N/A |
| UBS Emerging Markets Equity Opp P | |||
| FUGCX | 44.54 | -0.31 | -0.69% |
| Fidelity Advisor Utilities C | |||
| PLVIX | 21.02 | -0.16 | -0.76% |
| Principal Large Cap Value III Inst | |||
| FINFX | 90.17 | -0.75 | -0.82% |
| American Funds Fundamental Invs F2 | |||
| NSMAX | 33.35 | -0.44 | -1.30% |
| Nuveen Small/Mid-Cap Value A | |||